FDA Determines Regulatory Review Period for LYRICA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially approved the regulatory review period for the patent extension of LYRICA, a new drug application submitted by the pharmaceutical company, following a request to the Director of Patents and Trademarks at the US Department of Commerce.